Eisai

Views & Analysis

ASCO 2018 Preview – what to expect from this year’s conferen...

pharmaphorum will be presenting live online coverage of this year’s ASCO 2018 conference, the biggest event of the year for cancer medicine.

News

Merck shows canny cancer strategy in $5.76bn Eisai milestone...

Firms will co-develop Lenvima and Keytruda combinations

News

Eisai disappointed after NICE rejects earlier use for breast...

NICE says no to Halaven in second line breast cancer

News

NICE recommends funding for three thyroid cancer drugs

Eisai's drug finally funded after two year delay

News

NICE recommends Eisai's kidney cancer combination

NICE has recommended Eisai’s Kisplyx (lenvatinib) in combination with Novartis’ Afinitor (everolimus) in kidney cancer after the company further dropped its price.

News

3D Japan flag (with clipping path)see more country...

Eisai: UK gives pharma a poor deal, may invest elsewhere

Japanese pharma getting frustrated with NICE

ASCO 2018 Preview – what to expect from this year’s conferen...

Merck shows canny cancer strategy in $5.76bn Eisai milestone...

Eisai disappointed after NICE rejects earlier use for breast...

NICE recommends funding for three thyroid cancer drugs

NICE recommends Eisai's kidney cancer combination

Eisai: UK gives pharma a poor deal, may invest elsewhere

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

Eisai

Editor's Picks